Avalo Therapeutics (AVTX) Return on Capital Employed (2015 - 2026)
Avalo Therapeutics (AVTX) posted Return on Capital Employed of 81.97% for Q1 2026, down 21.21% on a QoQ basis from 67.62% in Q4 2025, and down 4570.0% year-over-year from 1.83% in Q1 2025.
Avalo Therapeutics (AVTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Avalo Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 81.97% for Q1 2026.
- Quarterly Return on Capital Employed fell 4570.0% year-over-year to 81.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.97% (down 4570.0% YoY) and the FY2025 annual result came in at 60.44%, up 2639.0% from the prior year.
- Return on Capital Employed was 81.97% for Q1 2026 at Avalo Therapeutics, down from 67.62% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.81% in Q1 2024 and bottomed at 291.53% in Q4 2022.
- A 5-year average of 142.21% and a median of 136.2% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 17056 bps — and 2024, when it jumped 25543 bps.
- Avalo Therapeutics' Return on Capital Employed stood at 291.53% in 2022, then surged by 54 bps to 133.33% in 2023, then soared by 56 bps to 58.24% in 2024, then retreated by 16 bps to 67.62% in 2025, then slipped by 21 bps to 81.97% in 2026.
- Business Quant data shows AVTX's Return on Capital Employed at 81.97% in Q1 2026, 67.62% in Q4 2025, and 56.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -107.40% |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 20.34% |
| 10 | Avalo Therapeutics | 397.71 Mn | 340.56 Mn | - | -81.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.97% |
| Dec 31, 2025 | -67.62% |
| Sep 30, 2025 | -56.41% |
| Jun 30, 2025 | -48.79% |
| Mar 31, 2025 | -36.27% |
| Dec 31, 2024 | -58.24% |
| Sep 30, 2024 | -147.19% |
| Jun 30, 2024 | -273.95% |
| Mar 31, 2024 | 35.81% |
| Dec 31, 2023 | -133.33% |
| Sep 30, 2023 | -137.59% |
| Jun 30, 2023 | -266.06% |
| Mar 31, 2023 | -219.63% |
| Dec 31, 2022 | -291.53% |
| Sep 30, 2022 | -286.69% |
| Jun 30, 2022 | -211.92% |
| Mar 31, 2022 | -136.20% |
| Dec 31, 2021 | -120.97% |
| Sep 30, 2021 | -132.68% |
| Jun 30, 2021 | -183.93% |